Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Ann Surg ; 2024 Jun 21.
Article in English | MEDLINE | ID: mdl-38904102

ABSTRACT

BACKGROUND: Patients with pancreatic cancer and obstructive jaundice routinely undergo endoscopic stent placement (ES). It is well known that ES causes bacterial contamination and infectious complications after pancreatic resection. OBJECTIVE: To compare short-term outcomes and survival in patients undergoing pancreatic head resection after preoperative ES vs preoperative surgical drainage (SD) via T-tube insertion. METHODS: Patients with obstructive jaundice who underwent SD or ES from 2016 to 2022 were identified from a prospective database. Outcome analyses included microbiological bile contamination, overall morbidity and assessment of the overall complication burden using the Comprehensive Complication Index (CCI). Overall survival was investigated by Kaplan‒Meier analysis. RESULTS: A total of 55 patients with SD were identified and matched with 110 ES patients. After the primary intervention, ES patients experienced more complications (ES: 17.3% vs. SD: 3.6%; P=0.013). The overall complication burden after pancreatic resection was higher in ES patients than in SD patients (CCI: 27.2 vs. 19.9; P=0.022). Additionally, bacterial contamination of the bile was more frequent in ES patients compared to SD individuals (94.3% vs. 7.1%; P<0.001) with similar bacteria in 83.3% of postoperative abdominal infections in ES patients. While overall survival did not differ between the two groups, patients with postinterventional complications after ES had an impaired survival compared to those without complications (11.3 mo vs. 20.4 mo; P=0.03). CONCLUSION: SD for obstructive jaundice in resectable pancreatic cancer is associated with a lower overall complication burden. Additionally, patients with complications after ES experience worse overall survival. These findings indicate to rethink our standards of treatment of obstructive jaundice in patients with pancreatic cancer.

2.
J Neuroinflammation ; 19(1): 274, 2022 Nov 19.
Article in English | MEDLINE | ID: mdl-36403002

ABSTRACT

BACKGROUND: Cerebral infection with the protozoan Toxoplasma gondii (T. gondii) is responsible for inflammation of the central nervous system (CNS) contributing to subtle neuronal alterations. Albeit essential for brain parasite control, continuous microglia activation and recruitment of peripheral immune cells entail distinct neuronal impairment upon infection-induced neuroinflammation. PACAP is an endogenous neuropeptide known to inhibit inflammation and promote neuronal survival. Since PACAP is actively transported into the CNS, we aimed to assess the impact of PACAP on the T. gondii-induced neuroinflammation and subsequent effects on neuronal homeostasis. METHODS: Exogenous PACAP was administered intraperitoneally in the chronic stage of T. gondii infection, and brains were isolated for histopathological analysis and determination of pathogen levels. Immune cells from the brain, blood, and spleen were analyzed by flow cytometry, and the further production of inflammatory mediators was investigated by intracellular protein staining as well as expression levels by RT-qPCR. Neuronal and synaptic alterations were assessed on the transcriptional and protein level, focusing on neurotrophins, neurotrophin-receptors and signature synaptic markers. RESULTS: Here, we reveal that PACAP administration reduced the inflammatory foci and the number of apoptotic cells in the brain parenchyma and restrained the activation of microglia and recruitment of monocytes. The neuropeptide reduced the expression of inflammatory mediators such as IFN-γ, IL-6, iNOS, and IL-1ß. Moreover, PACAP diminished IFN-γ production by recruited CD4+ T cells in the CNS. Importantly, PACAP promoted neuronal health via increased expression of the neurotrophin BDNF and reduction of p75NTR, a receptor related to neuronal cell death. In addition, PACAP administration was associated with increased expression of transporters involved in glutamatergic and GABAergic signaling that are particularly affected during cerebral toxoplasmosis. CONCLUSIONS: Together, our findings unravel the beneficial effects of exogenous PACAP treatment upon infection-induced neuroinflammation, highlighting the potential implication of neuropeptides to promote neuronal survival and minimize synaptic prejudice.


Subject(s)
Toxoplasma , Toxoplasmosis , Humans , Pituitary Adenylate Cyclase-Activating Polypeptide/pharmacology , Pituitary Adenylate Cyclase-Activating Polypeptide/therapeutic use , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Neuroinflammatory Diseases , Toxoplasmosis/complications , Toxoplasmosis/drug therapy , Nerve Growth Factors , Inflammation/drug therapy , Inflammation Mediators
3.
Infect Dis Ther ; 10(3): 1215-1225, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34251655

ABSTRACT

A growing body of evidence supports the premise that deficiencies of zinc and angiotensin-converting enzyme 2 (ACE2, a zinc enzyme) determine severity of coronavirus disease 2019 (COVID-19). ACE2 is part of the renin-angiotensin system (RAS) and acts as a feedback control system moderating blood pressure, keeping blood pressure within normal limits. For a virus to infect a person, the virus has to get inside the person's cells. The virus that causes COVID-19 uses ACE2 to get into the cell. Think of this like an invader from outer space attacking your car by getting in through your cruise control; the RAS is like the cruise control of your car. What happens next depends on how robust your cruise control is. If your cruise control is young and healthy perhaps very little happens; your car may slow down or speed up a bit. But if your cruise control is in poor condition the attack might disrupt the entire speed control system; your car may brake suddenly or speed out of control and crash. Feedback control systems (natural or man-made) are designed to keep dynamic systems in control, but under certain situations can drive the system completely out of control. The RAS is composed of two feedback loops: the ACE loop provides amplification, increasing pro-inflammatory cytokines and blood pressure; the ACE2 loop provides fine control and mitigates the vasoconstrictive, pro-inflammatory, and thrombotic actions of the ACE loop. Usually, there is balance, but in the setting of COVID-19, underlying deficiencies of zinc and ACE2 can lead to an imbalance. Exacerbated by the severe downregulation of ACE2 seen with viral entry, a "tipping point" is reached with loss of control of the RAS system resulting in increased angiotensin II (Ang II) causing downstream vasoconstriction, inflammation, and thromboses. These, in turn, lead to complications often seen in "severe COVID-19" such as acute respiratory distress syndrome (ARDS) or cytokine storm, often seen in high-risk patients in the second week of illness. This model suggests that supplemental zinc could replenish zinc in ACE2, stabilize the ACE2 axis, and prevent disruption of the RAS. This would prevent the vasoconstrictive, inflammatory, and thrombotic actions of Ang II, thus preventing the severe COVID-19 complications which cause the high morbidity and mortality seen in high-risk patients with underlying zinc deficiency. Zinc supplements are available, easy to use, and relatively safe. Randomized clinical trials are needed to confirm safety and efficacy of zinc supplementation to decrease severity of and morality from COVID-19 in high-risk patients. Since replenishment of zinc and active ACE2 in patients in whom these are deficient may take weeks, supplementation in high-risk populations prior to COVID infection may be required. Such supplementation should not replace vaccination but may be useful in populations for whom vaccination is not available or for populations exposed to viral variants to which available vaccines have insufficient coverage.

4.
PLoS One ; 9(9): e108389, 2014.
Article in English | MEDLINE | ID: mdl-25238233

ABSTRACT

BACKGROUND: The neuropeptide Pituitary adenylate cyclase-activating polypeptide (PACAP) plays pivotal roles in immunity and inflammation. So far, potential immune-modulatory properties of PACAP have not been investigated in experimental ileitis. METHODOLOGY/PRINCIPAL FINDINGS: Mice were perorally infected with Toxoplasma (T.) gondii to induce acute ileitis (day 0) and treated daily with synthetic PACAP38 from day 1 to 6 post infection (p.i.; prophylaxis) or from day 4 to 6 p.i. (therapy). Whereas placebo-treated control mice suffered from acute ileitis at day 7 p.i. and succumbed to infection, intestinal immunopathology was ameliorated following PACAP prophylaxis. PACAP-treated mice exhibited increased abundance of small intestinal FOXP3+ cells, but lower numbers of ileal T lymphocytes, neutrophils, monocytes and macrophages, which was accompanied by less ileal expression of pro-inflammatory cytokines such as IL-23p19, IL-22, IFN-γ, and MCP-1. Furthermore, PACAP-treated mice displayed higher anti-inflammatory IL-4 concentrations in mesenteric lymph nodes and liver and higher systemic anti-inflammatory IL-10 levels in spleen and serum as compared to control animals at day 7 p.i. Remarkably, PACAP-mediated anti-inflammatory effects could also be observed in extra-intestinal compartments as indicated by reduced pro-inflammatory mediator levels in spleen (TNF-α, nitric oxide) and liver (TNF-α, IFN-γ, MCP-1, IL-6) and less severe histopathological sequelae in lungs and kidneys following prophylactic PACAP treatment. Strikingly, PACAP prolonged survival of T. gondii infected mice in a time-of-treatment dependent manner. CONCLUSION/SIGNIFICANCE: Synthetic PACAP ameliorates acute small intestinal inflammation and extra-intestinal sequelae by down-regulating Th1-type immunopathology, reducing oxidative stress and up-regulating anti-inflammatory cytokine responses. These findings provide novel potential treatment options of inflammatory bowel diseases.


Subject(s)
Ileitis/drug therapy , Intestine, Small/drug effects , Pituitary Adenylate Cyclase-Activating Polypeptide/therapeutic use , Toxoplasmosis/drug therapy , Animals , Ileitis/parasitology , Ileitis/pathology , Immunity, Cellular/drug effects , Intestine, Small/immunology , Intestine, Small/pathology , Mice , Mice, Inbred C57BL , Parasite Load , Pituitary Adenylate Cyclase-Activating Polypeptide/administration & dosage , Time Factors , Toxoplasmosis/pathology
5.
Bratisl Lek Listy ; 115(1): 14-8, 2014.
Article in English | MEDLINE | ID: mdl-24471896

ABSTRACT

The depth of myometrial infiltration by endometrial cancer is an important prognostic factor. The examination of the depth of infiltration classifies the patients in the low- and high-risk groups, which influences the therapeutic approach. Transvaginal ultrasonography represents a first-choice diagnostic test for the assessment of the depth of myometrial infiltration as the time consumption and financial demands of magnetic resonance imaging need to be taken into account. In comparison with the MRI, the diagnostic accuracy of the transvaginal ultrasound depends more on the individual experience and professional potential of the examining physician. This fact can contribute to the heterogeneity of published results of transvaginal ultrasound on the determination of infiltration depth. Having in mind the aim to verify these indicators in our local conditions and environment, we decided to prospectively study 150 endometrial cancer patients who were examined with the transvaginal ultrasound in the period 1/2009 - 10/ 2011. Correlated firstly with the preoperative and then secondly with the definitive histopathological examination was the depth-of-infiltration-related data that had been taken from the ultrasound findings. The output being monitored was the exclusion or confirmation of the invasion exceeding half the thickness of myometrium. In our study, the diagnostic accuracy of the method reached 82.67 %, while the other indicators were as follows: sensitivity 92.31 %, specificity 79.28 %, positive predictive value (PPV) 61.02 %, negative predictive value (NPV) 96.7 %, the likelihood ratio of a positive test 4.455 and the likelihood ratio of a negative test 0.097. The results of the depth of myometrial infiltration examination and their comparison with the data from similarly oriented clinical studies entitle us to include this examination in the set of standard preoperative methods used for the examination of patients with endometrial cancer (Tab. 3, Fig. 5, Ref. 20).


Subject(s)
Adenocarcinoma/diagnostic imaging , Endometrial Neoplasms/diagnostic imaging , Endosonography/methods , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Adenocarcinoma, Clear Cell/diagnostic imaging , Adenocarcinoma, Mucinous/diagnostic imaging , Adenocarcinoma, Papillary/diagnostic imaging , Adult , Aged , Aged, 80 and over , Endometrial Neoplasms/pathology , Endometrial Neoplasms/surgery , Female , Humans , Hysterectomy , Magnetic Resonance Imaging , Middle Aged , Neoplasm Grading , Neoplasm Invasiveness , Neoplasm Staging , Ovariectomy , Predictive Value of Tests , Prognosis , Prospective Studies , Salpingectomy , Sensitivity and Specificity , Treatment Outcome , Vagina/diagnostic imaging
6.
Klin Onkol ; 25(5): 340-5, 2012.
Article in Slovak | MEDLINE | ID: mdl-23102195

ABSTRACT

Uterine sarcomas are a heterogeneous group, which constitutes about 8% of malignant uterine tumors. This heterogeneousness and rare occurrence were the main cause of non-uniform therapeutical management. In previously published papers, there were mainly retrospective assessments of the experience of individual centres. The basis of relevant conclusions of the studies, beside their prospectiveness, is the use of unified classification criteria. Currently, a completely new classification of uterine sarcomas is being used, which consists of leiomyosarcoma, endometrial stromal sarcomas and adenosarcomas. For classification of carcinosarcomas, there are valid new criteria of endometrial cancer classification. The basic therapeutic approach of leiomyosarcoma and endometrial stromal sarcomas is a surgical intervention. The gold standard is hysterectomy and salpingooophorectomy. Justifiability of lymphadenectomy is being discussed. For carcinosarcomas, the same recommendations as for the surgical treatment of prognostically unfavourable endometrial carcinoma are valid - hysterectomy, salpingooophorectomy, pelvic and paraaortal lymph node dissection and omentectomy. It is necessary to implement the new classification into clinical practice, to publish and evaluate existing papers, which take into account their basic thesis. Only then it will be possible to create unified therapies. They should be aimed to improve patients survival.


Subject(s)
Sarcoma , Uterine Neoplasms , Combined Modality Therapy , Female , Humans , Sarcoma/classification , Sarcoma/pathology , Sarcoma/therapy , Uterine Neoplasms/classification , Uterine Neoplasms/pathology , Uterine Neoplasms/therapy
7.
Klin Onkol ; 24(2): 133-6, 2011.
Article in English | MEDLINE | ID: mdl-21638997

ABSTRACT

BACKGROUNDS: Angiomyofibroblastoma (AMFB) is a rare histopathologic finding of the female lower genital tract. This tumor belongs to the group of mesenchymal tumors. Mesenchymal neoplasms of the modified genital skin and mucosa are uncommon. The majority of these lesions are seen in females and, collectively, they form a family of vulvovaginal soft tissue tumors. This family includes fibroepithelial stromal polyps, angiomyofibroblastoma, cellular angiofibroma, aggressive angiomyxoma, vaginocervical myofibroblastoma, vulvar leiomyomatosis, and other smooth muscle tumors. Angiomyofibroblastoma is a benign tumor, histologically very similar to pelvic aggressive angiomyxoma (AMM), a distinctive, locally infiltrative but non-metastasizing mesenchymal neoplasm with a tendency to occur in the female pelvic and perineal regions. CASE: 44 years old woman with angiomyofibroblastoma of cervix uteri. CONCLUSION: A recognition of this entity is important to avoid misdiagnosis of other angiomyxoid neoplasms. Furthermore, unlike other, more aggressive, mesenchymal tumors of the lower genital tract, AMFB shows benign behaviour.


Subject(s)
Uterine Cervical Neoplasms/pathology , Adult , Angiofibroma/pathology , Diagnosis, Differential , Female , Humans , Uterine Cervical Neoplasms/diagnosis
8.
Klin Onkol ; 24(1): 50-3, 2011.
Article in Slovak | MEDLINE | ID: mdl-21542276

ABSTRACT

HPV infections of the lower genital tract are associated with the increasing incidence of vulvar intraepithelial neoplasia. The new classification divides vulvar intraepithelial neoplasia according to its incidence into two groups: usual and differentiated type. The usual type occurs mainly in young women and is associated with HPV infection, the differentiated type is HPV-negative and occurs in older women. The diagnosis is based on biopsy from a suspicious lesion. The standard treatment involves surgical excision. Topical treatment is now being preferred in young women in order to preserve appearance of the genitalia and sexual function. The high risk of recurrence is the reason for strict monitoring of patients after treatment completion.


Subject(s)
Carcinoma in Situ , Vulvar Neoplasms , Carcinoma in Situ/diagnosis , Carcinoma in Situ/therapy , Carcinoma in Situ/virology , Female , Humans , Papillomavirus Infections/complications , Papillomavirus Infections/diagnosis , Papillomavirus Infections/therapy , Vulvar Neoplasms/diagnosis , Vulvar Neoplasms/therapy , Vulvar Neoplasms/virology
9.
J Craniomaxillofac Surg ; 36(1): 21-7, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17988886

ABSTRACT

OBJECTIVES: This study aimed at evaluating the clinical performance and osseointegration of short orthodontic implants immediately loaded with orthodontic forces. MATERIAL AND METHODS: The investigation was designed as an experimental animal study. Eight palatal implants of the Ortho-system were immediately loaded with 100 cN after palatal insertion in 4 female German shepherd dogs. Xylene orange and calcein green were used for polychrome sequential labelling. Histological preparation utilized the cutting and grinding technique. Outcome variables were clinical implant success, histological osseointegration and bone-to-implant contact rates. RESULTS: All (8/8) implants were clinically successful and stable when the animals were sacrificed. One implant showed fibrous encapsulation and was histologically classified as "failed" for "osseointegration". Upon morphometrical analysis, bone to implant contact rates for newly formed or remodelled bone were 19% at 4 weeks and 26% at 6 months. The fluorochrome labelling indicated substantial mineral apposition on the surface of the implants at the end of the first and the second postoperative months. CONCLUSION: This study revealed borderline reliability of osseointegration for immediately loaded palatal implants but reasonable bone formation at the 4th postoperative week. Thus, two clinical concepts are both supported: early orthodontic loading after 4 weeks as well as improvement of primary stability to provide a biomechanical basis for immediate orthodontic loading.


Subject(s)
Orthodontic Anchorage Procedures/instrumentation , Animals , Dental Stress Analysis , Dogs , Female , Implants, Experimental , Microscopy, Fluorescence , Orthodontic Anchorage Procedures/methods , Osseointegration , Palate, Hard/surgery , Pilot Projects , Time Factors
10.
AIDS Patient Care STDS ; 21(8): 533-43, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17711378

ABSTRACT

The additional 48-week optional treatment extension of the T-20 versus Optimized Regimen Only (TORO) studies evaluated long-term safety and efficacy of enfuvirtide (ENF) through week 96 in patients receiving ENF plus optimized background (OB) and patients switching to ENF plus OB from OB alone. Patient randomization was 2:1 to ENF plus OB (n = 663) and OB (n = 334), of which 89.7% and 89.8% were male, 89.3% and 88.6% were Caucasian, and median age was 41 and 42 years, respectively. HIV risk factors were comparable between the ENF plus OB and OB groups with the major factors being 65.2% versus 66.2% homosexual contact, 17.8% versus 19.8% heterosexual contact, 4.1% versus 4.8% bisexual contact, respectively, and 6.9% injection drug use in both groups. OB patients were allowed to switch to ENF plus OB at virologic failure before week 48 and required to switch at week 48 to continue in the study (n = 230). Efficacy and safety assessments were conducted for each group. At week 96, 55% of ENF plus OB subjects completed the study and 26.5% achieved a viral load of less than 400 copies per milliliter (17.5% achieved less than 50 copies per milliliter). Viral load and CD4 mean change from baseline was -2.1 and -1.1 log(10) HIV-1-RNA copies per milliliter and +166 and +116 CD4 cells/mm(3) for ENF plus OB and switch patients, respectively. No new ENF-related safety issues emerged in weeks 48-96. Injection site reactions led to discontinuation in 7% and 10% of ENF plus OB and switch patients, respectively. In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial.


Subject(s)
Anti-HIV Agents , HIV Envelope Protein gp41 , HIV Fusion Inhibitors , HIV-1/drug effects , Peptide Fragments , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/adverse effects , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , Drug Administration Schedule , Drug Therapy, Combination , Enfuvirtide , Female , HIV Envelope Protein gp41/administration & dosage , HIV Envelope Protein gp41/adverse effects , HIV Envelope Protein gp41/therapeutic use , HIV Fusion Inhibitors/administration & dosage , HIV Fusion Inhibitors/adverse effects , HIV Fusion Inhibitors/therapeutic use , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , Humans , Male , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , Peptide Fragments/therapeutic use , RNA, Viral/blood , Time Factors , Treatment Outcome , Viral Load
12.
J Infect Dis ; 194(9): 1319-22, 2006 Nov 01.
Article in English | MEDLINE | ID: mdl-17041859

ABSTRACT

The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean+/-SD elimination-rate constant for overall decay (0.142+/-0.040 per day and 0.128 +/- 0.033 per day in the 2- and 3-target arms, respectively; P>.1) or for modeled first-phase decay rate (-0.62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.


Subject(s)
HIV Envelope Protein gp41/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/drug effects , Oxazines/therapeutic use , Peptide Fragments/therapeutic use , Ritonavir/therapeutic use , Saquinavir/therapeutic use , Alkynes , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Benzoxazines , Cyclopropanes , Drug Therapy, Combination , Enfuvirtide , Female , HIV Envelope Protein gp41/administration & dosage , HIV-1/physiology , Humans , Male , Oxazines/administration & dosage , Peptide Fragments/administration & dosage , Ritonavir/administration & dosage , Saquinavir/administration & dosage , Viral Load
13.
J Acquir Immune Defic Syndr ; 40(4): 404-12, 2005 Dec 01.
Article in English | MEDLINE | ID: mdl-16280694

ABSTRACT

BACKGROUND: The T-20 Versus Optimized Background Regimen Only (TORO) 1 and TORO 2 clinical trials are open-label, controlled, parallel-group, phase 3 studies comparing enfuvirtide plus an optimized background (OB) of antiretrovirals (n = 661) with OB alone (n = 334) in treatment-experienced HIV-1-infected patients. METHODS: The primary objective at week 48 was to investigate durability of efficacy, as measured by the percentage of patients maintaining their week 24 response or improving. Efficacy analyses used the intent-to-treat population. RESULTS: A total of 73.7% of patients randomized to the enfuvirtide group remained on treatment through week 48 versus 21.3% originally randomized to the control group. At week 48, a higher proportion of week 24 responders maintained their response or were new responders in the enfuvirtide group than in the control group in each responder category: HIV-1 RNA level > or =1.0 log(10) change from baseline, <400 copies/mL and <50 copies/mL (37.4%, 30.4%, and 18.3% in the enfuvirtide group vs. 17.1%, 12.0%, and 7.8% in the control group, respectively; P < 0.0001 for all comparisons). CD4 cell count increases from baseline were twice as great in the enfuvirtide group as in the control group. CONCLUSION: These data demonstrate durable efficacy of enfuvirtide plus OB over 48 weeks.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Envelope Protein gp41/therapeutic use , HIV Fusion Inhibitors/therapeutic use , HIV Infections/drug therapy , HIV-1 , Peptide Fragments/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Anti-HIV Agents/administration & dosage , CD4 Lymphocyte Count , Drug Therapy, Combination , Enfuvirtide , Female , HIV Envelope Protein gp41/administration & dosage , HIV Fusion Inhibitors/administration & dosage , HIV Infections/immunology , HIV Infections/physiopathology , HIV Infections/virology , HIV-1/drug effects , Humans , Male , Middle Aged , Peptide Fragments/administration & dosage , RNA, Viral/blood , Time Factors , Viral Load
14.
J Acquir Immune Defic Syndr ; 40(4): 413-21, 2005 Dec 01.
Article in English | MEDLINE | ID: mdl-16280695

ABSTRACT

BACKGROUND: Antiretroviral tolerability is a critical factor contributing to treatment outcome. The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients. METHODS: A total of 997 patients were randomized at a 2:1 ratio to an optimized background antiretroviral regimen plus enfuvirtide (n = 663) or an optimized background regimen alone (control group; n = 334). Control patients could switch to enfuvirtide on virologic failure. RESULTS: In total, 26.5% of patients randomized to enfuvirtide and 36.6% to the control group discontinued study treatment before week 48; the percentage of patients withdrawn for safety reasons (including adverse events [AEs], deaths, and laboratory abnormalities) was 14.0% in the enfuvirtide group and 11.6% in the control group. Injection site reactions (ISRs) occurred in 98% of enfuvirtide patients and led to treatment discontinuation in 4.4%. Treatment-related (defined as possibly, probably, or remotely) AE rates per 100 patient-years were lower with enfuvirtide (96.2) than in the control group (149.9); diarrhea, nausea, and fatigue, the most frequently reported AEs, were significantly less frequent with enfuvirtide than in the control group. Pneumonia was significantly more frequent in patients treated with enfuvirtide (6.7 vs. 0.6 events per 100 patient-years), although the incidence was within expected ranges for this population. Lymphadenopathy was also higher in enfuvirtide-treated patients (7.1 vs. 1.2 events per 100 patient-years) for control patients. CONCLUSION: The addition of enfuvirtide to an optimized background regimen does not exacerbate AEs commonly associated with antiretrovirals. ISRs limited treatment in <5% of patients.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Envelope Protein gp41/adverse effects , HIV Fusion Inhibitors/adverse effects , HIV Infections/drug therapy , HIV-1 , Peptide Fragments/adverse effects , Adult , Diarrhea , Drug Therapy, Combination , Enfuvirtide , Fatigue , HIV Envelope Protein gp41/administration & dosage , HIV Envelope Protein gp41/therapeutic use , HIV Fusion Inhibitors/administration & dosage , HIV Fusion Inhibitors/therapeutic use , Humans , Lymphatic Diseases , Nausea , Peptide Fragments/administration & dosage , Peptide Fragments/therapeutic use , Pneumonia
15.
AIDS ; 18(13): 1787-94, 2004 Sep 03.
Article in English | MEDLINE | ID: mdl-15316339

ABSTRACT

BACKGROUND: Enfuvirtide (ENF) is the first of a novel class of drugs that block HIV gp41-mediated viral fusion to host cells. Viruses with mutations at positions 36-38 in HIV-1 gp41 and/or reduced susceptibility to ENF have been selected both in vitro and in vivo. METHODS: An analysis of baseline and on-treatment ENF susceptibility in virus samples from Phase II clinical trial patients treated with ENF as functional monotherapy for 28 days (TRI-003) or in combination with oral antiretrovirals for >/= 48 weeks (T20-205, T20-206 and T20-208). Population sequencing identified amino acid (aa) substitutions at positions 36-45 of gp41 in plasma HIV-1. ENF susceptibility of virus isolates was tested in the cMAGI assay and viral DNA was sequenced for selected isolates. RESULTS: HIV-1 gp41 aa 36-45 were highly conserved in virus from ENF-naive patients, except for a 15% incidence of N42S which did not reduce sensitivity to ENF. Virus from patients experiencing viral load rebound exhibited reduced susceptibility to ENF and substitutions in gp41 aa 36-45. The most common substitutions observed on treatment were at positions 36, 38, 40, 42 and 43. On-treatment changes in the phenotypic susceptibility of virus isolates to ENF were generally associated with genotypic changes in aa 36-45. There was a relatively lower incidence of ENF resistance in patients with baseline sensitivity to more oral antiretrovirals in comparison to patients sensitive to fewer antiretrovirals. CONCLUSIONS: These data identify the importance of HIV-1 gp41 aa 36-45 in the emergence of resistance to ENF.


Subject(s)
Drug Resistance, Viral/genetics , HIV Envelope Protein gp41/therapeutic use , HIV Fusion Inhibitors/therapeutic use , HIV Infections/drug therapy , HIV-1/genetics , Peptide Fragments/therapeutic use , Adult , DNA, Viral/genetics , Enfuvirtide , Genotype , HIV Envelope Protein gp41/genetics , HIV Infections/genetics , Humans , Middle Aged , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...